SEE ALL VIDEOS

Start activity

touchEXPERT OPINIONS

Experts answer questions with in-depth advice on the current clinical landscape and how new therapies and guidance might impact regional clinical practice. Useful tips below will show how to navigate the activity. Close

Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management

Professor Andrew Wei is a clinical haematologist, National Health and Medical Research Council clinical fellow and co-stream lead for acute leukaemia and myelodysplastic syndromes at the Peter MacCallum Centre and the Royal Melbourne Hospital in Melbourne, Australia. read more

Prof. Wei holds a joint appointment as the Metcalf Family fellow and a laboratory head in the division of Blood Cells and Blood Cancer at the Walter and Eliza Hall Institute of Medical Research (WEHI) and has served for more than a decade as chair of the Acute Leukaemia and Myelodysplastic Syndrome Working Party for the Australasian Leukaemia & Lymphoma Group.

Prof. Wei is an internationally recognized expert in the field of AML and has led several clinical trial programmes. The research activity of his laboratory at WEHI focuses on novel drugs and mechanisms of drug resistance in AML. Prof. Wei has authored more than 200 peer-reviewed publications, predominantly in the field of AML, and has more than 13,000 literature citations.

Prof. Wei discloses: Advisory board/panel fees from AbbVie, Agios, Amgen, Astellas, AstraZeneca, Beigene, Bristol Myers Squibb, Gilead, Janssen, Jazz, Novartis, Pfizer, Roche, Servier. Consultancy fees from AbbVie, Aculeus, Novartis, Servier, Shoreline. Grants/research support from AbbVie, Astex, AstraZeneca, Bristol Myers Squibb, Janssen, Novartis, Servier, Syndax [Amgen to institution]. Other financial or material support (royalties, patent, etc.) Prof. Wei is an employee of the Walter and Eliza Hall Institute (WEHI). WEHI receives milestone and royalty payments related to drug development. Current and past employees of WEHI may be eligible for financial benefits related to these payments. Prof. Wei receives such a financial benefit. Speaker’s bureau fees from AbbVie, Astellas, Bristol Myers Squibb, Novartis, Servier.

Prof. Agnieszka Wierzbowska is head of the Department of Hematology at the Medical University of Łódź, Copernicus Memorial Hospital in Łódź, Poland. read more

Prof. Weirzbowska became chief of the Leukaemia and Bone Marrow Transplantation Unit in the Department of Hematology in 2012. She has been a professor of medicine and vice dean for science within the medical faculty since 2016.

Prof. Wierzbowska has experience in clinical haematology, experimental haematology, bone marrow transplantation and internal disease. Her research interests are in developmental therapeutics for acute leukaemia, MDS and transplantation. She has served as the principal investigator on several clinical trials and has authored or co-authored numerous publications and abstracts. She sits on the editorial boards and acts as a reviewer for several journals. Since 2010, she has been a leader of the AML Working Group for the Polish Adult Leukemia Group.

Prof. Wierzbowska is a member of the American Society of Hematology, the European Hematology Association, the European Society for Blood and Marrow Transplantation, and the European Steering Committee of AML Hub, as well as an ambassador of Know AML. She has played an active role as a speaker and panellist at numerous regional, national and international conferences.

Prof. Wierzbowska discloses: Research grants from Jazz Pharmaceuticals. Honoraria from AbbVie, Astellas, Bristol Myers Squibb/Celgene, Gilead/Kite, Janssen, Novartis, Pfizer, Servier. Advisory board fees from AbbVie, Astellas, BerGenBio, Bristol Myers Squibb/Celgene, Gilead/Kite, Janssen, Novartis, Pfizer, Servier.

Prof. Gert Ossenkoppele was appointed as professor of haematology at the VU University Medical Center in Amsterdam in 2003. He now has an honorary position as haematologist at the Amsterdam University Medical Center. read more

Prof. Ossenkoppele’s research interests are mainly translational and include the biology of acute myeloid leukaemia (AML), leukaemic stem cell target discovery, immunotherapy and measurable residual disease detection using flow cytometry to inform treatment of AML. He is the principal investigator of national and international clinical trials in myeloid malignancies.

Prof. Ossenkoppele has authored over 450 publications in peer-reviewed journals and has been an invited speaker at many national and international scientific meetings. He is a reviewer, on a regular basis, for many high-impact haematological journals (Blood, Leukemia, Haematologica, JAMA Oncology, Lancet Oncology and New England Journal of Medicine).

Prof. Ossenkoppele is a member of and fulfils a mentorship role in the AML working party of HOVON (Dutch-Belgian Hematology Trial Group). He is a lead participant of the AML work package (WP) of the European LeukemiaNet (ELN) and a board member of the ELN foundation. He co-leads the AML WP of HARMONY (Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology). He is also a member of the AML Scientific working group of the European Hematology Association.

Prof. Ossenkoppele is a member of the Global and EU steering committee of the AML Hub, an educational portal for haematologists.

Prof. Ossenkoppele discloses: Advisory board fees from AGIOS, Amgen, Astellas, Bristol Myers Squibb, Celgene, Gilead, JAZZ Pharmaceuticals, Johnson & Johnson, Novartis, Pfizer, Roche, Servier. Consultancy fees from Celgene, Johnson & Johnson, Pfizer, Roche. Research support from Celgene, Johnson & Johnson, Novartis.

Useful tips

Select in the video player controls bar to choose subtitle language. Subtitles available in English, Simplified Chinese.
Downloads including slides are available for this activity in the Toolkit

Learning Objectives

After watching this activity, participants should be better able to:

Describe the clinical presentation and the diagnostic process for MDS and AML
Demonstrate how the pathophysiology of MDS and AML determines disease classification
Outline the updated risk stratification guidelines for MDS and AML and the implications for patient management

Overview

In this activity, three experts provide their insights into the impact of the 2022 updates of the World Health Organization (WHO) and International Consensus Classification (ICC) guidelines on the diagnosis, classification and management of HR-MDS and AML. The clinical application of the Molecular International Prognostic Scoring System (IPSS-M) is also discussed.

This activity is CE/CME accredited

To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

Claim Credit

Useful tips

Select in the video player controls bar to choose subtitle language. Subtitles available in English, Simplified Chinese.
Downloads including slides are available for this activity in the Toolkit

Log into your Touch Account

Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.

Error:

Forgot Password?

Or log in with

By proceeding, you agree to our terms & conditions.

For information about how we
use your data, see our privacy policy.

Register now for FREE Access

Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.

Already have an Account?

Sign up with an Email

Or use a Social Account.

Error:

By clicking sign up you agree to the website
terms & conditions and privacy policy.

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Listen on the go

Downloads

Share this activity

Feedback

Feedback

Feedback

You may also be interested in...

touchCONGRESS

Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024

CONFERENCE HUB

Revumenib in relapsed/refractory KMT2Ar acute leukaemia – AUGMENT-101 phase 2 study: Ibrahim Aldoss, ASH 2023

CONFERENCE HUB

Mark Levis, EHA 2023: MORPHO trial of gilteritinib as post-transplant maintenance for FLT3-ITD acute myeloid leukaemia